

REVIEW

Role of tumor suppressor genes in the cancer-associated reprogramming of human induced pluripotent stem cells

Ying-Chu Lin^{1,2}, Yoshinobu Murayama³, Koichiro Hashimoto⁴, Yukio Nakamura⁵, Chang-Shin Lin^{6,7}, Kazunari K Yokoyama^{6*} and Shigeo Saito^{8,9*}

Abstract

Because of their pluripotent characteristics, human induced pluripotent stem cells (iPSCs) possess great potential for therapeutic application and for the study of degenerative disorders. These cells are generated from normal somatic cells, multipotent stem cells, or cancer cells. They express embryonic stem cell markers, such as OCT4, SOX2, NANOG, SSEA-3, SSEA-4, and REX1, and can differentiate into all adult tissue types, both *in vitro* and *in vivo*. However, some of the pluripotency-promoting factors have been implicated in tumorigenesis. Here, we describe the merits of tumor suppressor genes as reprogramming factors for the generation of iPSCs without tumorigenic activity. The initial step of reprogramming is induction of the exogenous pluripotent factors to generate the oxidative stress that leads to senescence by DNA damage and metabolic stresses, thus inducing the expression of tumor suppressor genes such as *p21^{CIP1}* and *p16^{INK4a}* through the activation of p53 to be the pre-induced pluripotent stem cells (pre-iPSCs). The later stage includes overcoming the barrier of reprogramming-induced senescence or cell-cycle arrest by shutting off the function of these tumor suppressor genes, followed by the induction of endogenous stemness genes for the full commitment of iPSCs (full-iPSCs). Thus, the reactive oxygen species (ROS) produced by oxidative stress might be critical for the induction of endogenous reprogramming-factor genes via epigenetic changes or antioxidant reactions. We also discuss the critical role of tumor suppressor genes in the evaluation of the tumorigenicity of human cancer cell-derived pluripotent stem cells, and describe how to overcome their tumorigenic properties for application in stem cell therapy in the field of regenerative medicine.

Introduction

Reprogramming of induced pluripotent stem cells and tumorigenic properties

Stem cells with the capacity to differentiate into all adult tissue types can be derived from the inner cell mass of the mouse blastocyst [1]. These embryonic stem cells (ESCs) are unique resources for the research of cell development and differentiation, with the ultimate aim of repairing damaged tissues and organs in humans. The reprogramming of differentiated mammalian somatic cells into an undifferentiated pluripotent state was first demonstrated by the birth of viable young sheep after nuclear transfer of adult somatic cells into unfertilized enucleated oocytes

[2]. However, the approaches used to obtain pluripotency in humans, such as the nuclear transfer of somatic cells or the fusion of somatic cells with ESCs, have always been associated with ethical concerns that interfere with the application of these types of cells in basic research and clinical therapy. The successful reprogramming of mouse somatic cells to induced pluripotent stem cells (iPSCs) by the enforced expression of pluripotency factors [3] has paved the way for autologous cell-based therapeutic applications and the study of degenerative disorders. Subsequent reports have demonstrated that iPSCs are highly similar to ESCs when tested using a serial set of assays [4-6]. The use of such cells can circumvent the ethical concerns described above.

The core ESC regulatory circuitry involves OCT4, SOX2, and NANOG, which regulate their own expression and the expression or suppression of other factors involved in self-

* Correspondence: kazu@kmu.edu.tw; saict1@maple.ocn.ne.jp

⁶Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, 100 Shin-Chuan 1st Road, Kaohsiung 807, Taiwan

⁸Saito Laboratory of Cell Technology, Yaizu, Tochigi 329-1571, Japan

Full list of author information is available at the end of the article

renewal, pluripotency, and dedifferentiation [7-10]. Recently, two reports showed that TFCP2L1 is another critical factor for nuclear reprogramming [11,12]. Several studies have shown that the activation of the Wnt pathway can cause ESCs to remain pluripotent [13-17]. In contrast, other studies demonstrated that the Wnt pathway controls the differentiation of ESCs and the terminal differentiation of postmitotic cells [18,19]. Furthermore, another group observed that OCT4 regulates pluripotency via nuclear β -catenin degradation, thereby antagonizing Wnt- β -catenin signaling, and that the downregulation of OCT4 increases β -catenin protein levels, thus enhancing Wnt signaling and initiating the differentiation of ESCs [20]. Some of the pluripotency factors used to generate iPSCs have been implicated in tumorigenesis, indicating that reprogramming and cellular transformation might occur via related pathways [8,21-23]. Interestingly, the inhibition of the tumor suppressor p53 (the product of the human *TP53* and mouse *Trp53* genes) enhances the reprogramming of fibroblasts into iPSCs [24] and can generate transformed cancer stem cells from differentiated cells [25]. The efficacy of the nuclear reprogramming of cancer cells with mutated p53 or deleted p53 is increased to generate iPSCs; however, the frequency of tumorigenesis is also clearly increased in these reprogramming cancer stem cells [26]. Thus, none of the traditional models incorporates the possibility of tumor-associated cellular reprogramming and the plasticity associated with the loss of p53 function. Therefore, the tumorigenicity risk associated with these stem cells must be removed before the achievements observed in basic research can be safely translated into clinical applications.

In this review, we summarize the connection between tumor suppressor genes (to avoid the emergence of tumor cells) and full reprogramming to iPSCs. We address the question of whether cancer-cell-specific iPSCs are equivalent to other types of stem cells, such as fully committed iPSCs (full-iPSCs), from the point of view of overcoming their tumorigenic properties.

Role of gatekeeping tumor suppressors in stem cells

Stem cell genomes must be rigorously 'guarded' throughout each developmental stage because such cells expand periodically to enable tissue repair and replacement. Thus, as faithful genomic duplication over a lifetime is restricted to minimize the accumulation of oncogenic lesions during such expansions, inadequate genomic stability control would be especially deleterious in ESCs because they are the progenitors of all adult organ systems. Gatekeeping tumor suppressors, such as p16^{INK4a}, p14^{ARF}, and p53, negatively regulate cellular proliferation and survival [27]. These gene products were first discovered by virtue of their role in cancer, but probably evolved to regulate homeostasis in normal tissues by

regulating the proliferation and survival of normal cells. Gatekeeping tumor suppressors tend to negatively regulate stem cell function [28] and regulate stem cell aging because their expression and/or function increase with age [29-31]. Elevated p53 expression or constitutive p53 activation can deplete stem cells [32], causing premature aging, and shorten life-span despite reducing cancer incidence [33-35]. These effects in mice also appear to reflect similar functions in humans because a polymorphism in p53 that reduces p53 function increases cancer incidence and life-span in humans [36]. This suggests that increased p53 activity protects against cancer but can promote aging and shorten life span, at least when a certain threshold of activity is reached. The functions of the p16^{INK4a}, p14^{ARF}, and p53 tumor suppressors depend on expression level and context, thus promoting the maintenance of mitotically active cells in some contexts, while promoting cell death or senescence in other contexts. For example, p53 promotes the maintenance of genome integrity [37] and promotes tissue generation in ATR mutant mice by promoting DNA repair and/or by promoting the death of cells with DNA damage [38]; however, in response to oncogenic stimuli or telomere attrition, p53 depletes stem cells [32,39]. Overall, gatekeeping tumor suppressors have pleiotropic functions that promote stem cell functions in some ways and negatively regulate them in other ways, with complex and context-dependent consequences for aging.

Deficiency of p53 and stemness characteristics


Although p53 mutation and pathway inactivation are found in the majority of tumors, they appear to be especially concentrated among tumors that exhibit plasticity and loss of differentiation characteristics [40-42]. Selection for p53 functional inactivation during cancer progression has typically been attributed to the survival benefits that result from reduced apoptosis, cell cycle arrest, and increased opportunities for cellular evolution afforded by genomic instability. In light of the above discussion, however, it is also possible that p53 loss destabilizes the differentiated state and enables reversion to a more stem-like state. It is well known that the inhibition of the p53 pathway increases the apparent efficiency of iPSC generation dramatically [43-47]. The downregulation of genes that contribute to cell-cycle arrest or apoptosis also increases reprogramming. For example, although a mutation in MDMX reduced p53 activity by only two-fold at baseline, it increased reprogramming efficiency dramatically [45]. These results have several important implications. First, subtle changes in p53 activity are all that is required to increase the probability of reprogramming. Second, reprogramming is limited by a variety of p53-induced protective pathways, including, but not limited to, those involved in cell-cycle arrest, senescence, and apoptosis. Third,

through its ability to inhibit cell-cycle progression, p53 provides a potent barrier to the acquisition of the dedifferentiation involved in iPSC formation. Understanding of the mechanisms via which p53 limits reprogramming is complicated by the various methods used for the introduction of the reprogramming factors, as well as by the expression levels of these factors. In terms of stress induction, however, all these commitments are similar in the case of the induction of oxidative stress and production of reactive oxygen species (ROS).

Roles of reactive oxygen species and tumor suppressor genes during reprogramming

The cellular damage caused by free radicals may generate ROS as a consequence of oxidative phosphorylation in the mitochondrial electron transport chain [48]. ROS, such as superoxide and hydroxyl radical, are highly reactive and can damage mitochondrial and nuclear DNA, as well as proteins and lipids, by modifying them chemically. Nuclear reprogramming induced by Yamanaka factors involves extensive chromatin remodeling and resets the epigenetic program to generate iPSCs [49]. This conventional iPSC technique using virus-mediated gene transfer is now a common method to deliver reprogramming factors [50]. In fact, the virus infection-induced immune response, like innate immunity, can result in accumulation of ROS [51,52]. Alternative reprogramming methods without virus infection might be useful to increase the survival rate of iPSCs due to less ROS production. Stem cells appear to be particularly sensitive to elevated ROS levels. Increased ROS levels resulting from metabolic changes in iPSCs may hinder the survival of reprogrammed cells, as suggested by observations of iPSC-generation under hypoxic conditions [53,54]. In addition, mitochondrial functions are also repressed in iPSCs or human ESCs [55], suggesting that ROS generation by reprogramming factors is unfavorable to the generation of iPSCs. Vitamin C has been reported to be an effective chemical to boost iPSC generation. Treatment with vitamin C reduced p53/p21 levels, which are the main barrier to successful reprogramming [56]. Wang *et al.* [57] found that the histone demethylases Jhdm1a/1b are the direct downstream effectors of vitamin C, in addition to antioxidant activity. Jhdm1b promotes cell-cycle progression and suppresses senescence by repressing the INK4a/ARF locus during reprogramming. Furthermore, inhibition of the mammalian target of rapamycin (mTOR) pathway by rapamycin, PP242, or the insulin/insulin growth factor-1 (IGF-1) signaling pathway notably enhances the efficiency of reprogramming [58]. Based on the concept that reprogramming is a stressful process that activates apoptosis and cellular senescence, it was shown that targeting the mTOR pathway alleviates the senescence imposed by the DNA damage response [59].

In addition, it was reported that senescence impairs the reprogramming to iPSCs, and that reprogramming triggers a stress response of senescence at the initial stage [60]. In fact senescence is the irreversible arrest during the G1 transition of the cell cycle that is elicited by replicative exhaustion or in response to stresses such as DNA damage, drugs, or oncogenes. Moreover, oxidative stress also induces the cellular apoptosis and autophagy. These arrests are implemented primarily through the activation of p53 and the upregulation of the cyclin-dependent kinase inhibitors p16^{INK4a} and p21^{CIP1} [61]. The introduction of Yamanaka factors initially triggers stress responses with characteristics of oxidative stress-like increases in the oxidized 8-oxoguanine and reprogramming-induced senescence (RIS) by upregulating p53, p16^{INK4a}, and p21^{CIP1} at the initial stage (pre-induced pluripotent stem cells (pre-iPSCs)). This upregulation of p16^{INK4a} and p21^{CIP1} was observed in heterokaryon-based reprogramming [62], suggesting the existence of an inherent link between senescence and reprogramming. Subsequently, the elevated levels of p16^{INK4a} and p21^{CIP1} that were detected in pre-iPSCs were decreased at a later stage in mouse embryonic fibroblasts, and increased levels of p53 and p21^{CIP1} in IMR90 cells were also decreased at a later stage [60,63,64]. The inhibition of senescence using knock-down constructs of p53, p21^{CIP1}, and p16^{INK4a} at the late stage finally improved the efficiency of the reprogramming of somatic cells or primary cancer cells, and the resulting iPSCs displayed characteristics of pluripotent stem cells (full-iPSCs) [60,65]. Other reports have confirmed the involvement of these two steps in reprogramming to full-iPSCs. Pre-iPSCs that failed to reprogram fully are trapped in a late step of reprogramming [63]. Inhibition of DNA methylation, knockdown of lineage-specific genes, or treatment with two inhibitors [66] can either convert some of these pre-iPSCs to full-iPSCs, or increase the proportion of fully reprogrammed iPSCs versus pre-iPSCs. The inhibition or the alleviation of senescence can increase the number of cells that surpass the early barrier imposed by RIS, resulting in a higher number of both pre-iPSCs and fully reprogrammed iPSCs. A combination of both strategies may be used synergistically to enhance reprogramming efficiency. RIS and probably reprogramming-induced apoptosis act as an initial barrier that limits the efficiency of the reprogramming. The reprogramming is slower and stochastic, suggesting the existence of a barrier that limits its efficiency. To increase the efficiency of reprogramming, the repression of RIS or reprogramming-induced apoptosis is definitely required at the late stage followed by a decrease in the expression of p16^{INK4a}, p21^{CIP1}, and p53 by hypoxic or other conditions, which are necessary for full reprogramming [43,45-47,67,68] (Figure 1).



The tumor suppressor p53 has been studied most extensively as a pivotal signal that converts diverse upstream stresses into downstream responses, including cell-cycle arrest, senescence, DNA repair, reprogramming, and programmed cell death [70]. p53 has been implicated as an enforcer of differentiation by virtue of its ability to limit the stem cell characteristic of self-renewal in several systems [65,71]. Together with the demonstration by Yamanaka that differentiated cells can be reprogrammed to a dedifferentiated state [67], and the demonstration that p53 is a potent reprogramming barrier [43-47,53,68], this has led to a resurgence of interest in the idea that loss of differentiation [72] may be linked to p53 pathway disruption in tumors. Recent studies have provided additional evidence of the link between p53 and the emergence of dedifferentiated, stem-like phenotypes [73]. The implications of these findings are far-reaching and will cause us to reconsider the role played by p53 inactivation in tumor pathophysiology and, more generally, the relationship between stem cells and cancer. Thus, reprogramming requires two stages:

the initial stage includes ROS production induced by reprogramming factors, which leads to the reprogramming changes or DNA damage that induce the expression of $p16^{INK4a}$, $p21^{CIP1}$ and p53. At this late stage, these alterations should be shut down by reducing expression of p53, $p21^{CIP1}$, and $p16^{INK4a}$ via hypoxic conditions or the expression of stemness genes such as *OCT4*, *SOX2*, *NANOG*, or other pluripotent genes (Figure 1).

The efficacy of reprogramming is indeed increased by several fold, but these iPSCs reprogrammed from cancer cells sometimes maintain or produce p53 mutations, resulting in tumor formation. Several genes in the original Yamanaka iPSC cocktail, such as *c-MYC*, generate oncogenic stresses that activate the p53 pathway to induce cell-cycle arrest or death [74]. Consequently, *c-MYC* expression, together with general tissue culture stresses, would be expected to activate p53 during the generation of iPSCs, to reduce reprogramming frequency or rate. These results have several important implications. First, subtle changes in p53 activity are all that is needed to increase the probability of reprogramming. At initial stages, the

reprogramming factors induce ROS production by DNA damage and repair function and, at a later stage, these ROS should be suppressed by the antioxidation system of cells or other epigenetic changes [75]. At this stage, p53-related pathways are required for epigenetic chromatin changes. Second, reprogramming is limited by a variety of p53-induced protective pathways during the late stage. Finally, through its ability to inhibit cell-cycle progression, p53 provides a potent barrier to the acquisition of the epigenetic changes that underlie the dedifferentiation involved in iPSC formation. Thus, p53-dependent pathways are required to inhibit the mutation of cells at the initial stage. Subsequently, to overcome p53-dependent senescence, cell-cycle arrest, and apoptosis, p53 downregulation by epigenetic reprogramming via the induction of stemness genes is required. A controllable system that was used to analyze reprogramming kinetics indicated that p53 inhibition enhances the generation of iPSCs probably through cell-cycle acceleration [76], although the data did not exclude the possible involvement of cell-cycle-independent contributions.

Reduction of the risk of tumorigenicity during the reprogramming of induced pluripotent stem cells

New cancer therapies based on the reprogramming approach using oncogenic pluripotency factors might increase the risk of tumor formation. Therapies that enhance the expression of tumor suppressor genes such as

p53, *p16^{INK4a}*, *p14^{ARF}* and *p21^{CIP1}*, accompanied by at least one pluripotency factor (OCT4 or SOX2) used with a plasmid-delivery system to target cancer cells, seem more advantageous. This combination inhibits ROS production first and reduces the expression of tumor suppressor genes via the induction of endogenous stemness genes. This method of iPSC generation is efficient and effective without any mutation of tumor suppressor genes, thus resulting in the generation of normal, non-mutated iPSCs (Figure 2).

It is commonly recognized in the field of stem cell research and regenerative medicine that tumorigenic risks must be overcome before the start of human iPSC-based clinical applications. Several possible risks need to be avoided: (i) the prolonged adaptation of human ESCs in culture conditions often results in gains of chromosomes 12 and 17 [78-80] and iPSCs [81], which might induce tumor formation; (ii) iPSCs derived from normally discarded human placental tissues, such as the amnion, chorion, umbilical cord, or fetal blood, might minimize the acquisition of genetic and epigenetic alterations, and, therefore, might be safer than iPSCs derived from adult somatic cells or cancer cells [82,83] (Table 1). Cultured human amniotic membrane-derived cells can differentiate into cells of all three germ layers under both *in vitro* and *in vivo* conditions [84,85]. In fact, primary amniotic tissues have low immunogenicity and anti-inflammatory properties [86,87], and the expression of putative immunosuppressive




Table 1 Characteristics of various types of pluripotent stem cells

Stem cell type	Donor cell type	Reprogramming factors/systems	Teratoma formation	Chimera formation	Pluripotency marker expression			Reference
					SSEA1	SSEA3/4	OCT4,SOX2, NANOG	
MESCs	Embryo	-	+	+	+	-	+	[9]
HESCs	Embryo	-	+	ND	-	+	+	[7]
MEpiSCs	Epiblast	-	+	-	+	-	+	[90]
MiPSCs	Neural stem cell	OCT4, viral	+	+	+	-	+	[91]
HiPSCs	Amnion	SOX2, plasmid electroporation	+	ND	-	+	+	[82]
MiPSCs-C	Melanoma	OCT4, c-MYC, KLF4, viral	+	+	ND	ND	ND	[43]
HiPSCs-C	Colorectal cancer	OCT4, c-MYC, SOX2, KLF4, viral	+	ND	-	+	+	[92]
HiPSCs-C	Melanoma	miRNA, viral	+	ND	-	+	+	[93]

Human and murine pluripotent stem cells are characterized as described in the cited references. HESCs, human embryonic stem cells; HiPSCs, human induced pluripotent stem cells; HiPSCs-C, human induced pluripotent stem cells from cancer; MEpiSCs, murine epiblast stem cells; MESCs, murine embryonic stem cells; MiPSCs, murine induced pluripotent stem cells; MiPSCs-C, murine induced pluripotent stem cells from cancer; ND, not determined.

factors, such as CD59 and CD73, is lost during the reprogramming process [88]. The loss of those factors in reprogrammed human amniotic membrane-derived iPSCs might benefit their potential therapeutic application. Up-regulated CD44 expression may be a surrogate marker of p53 inactivation and associated plasticity; thus, we will screen for the risk of developing tumorigenicity using this CD44 marker [89]. These approaches to avoid the cause of tumorigenicity might be useful when we treat stem cells or iPSCs with cancer-inducing agents, or when generating full reprogramming stem cells from somatic cells.

Merits of reprogrammed cancer cells as a cancer model

These reprogrammed cancer cells from cancer patients may alternatively be used to find genetic and epigenetic clues as to how the nuclear reprogramming was blocked when generating fully competent iPSCs or stem cells. Indeed, reprogrammed cancer cells generated from patients for the induction of pluripotent cells provided a potential cell-based therapy model to restore tissues or organs destroyed by chemotherapy, even though these cells are not fully pluripotent cells [89]. Accumulating evidence indicates that the epigenetic mechanism affects the properties of reprogrammed iPSCs, and appears to retain epigenetic imprinting associated with their tissue type of origin [94]. Thus, epigenetic mechanisms have been recognized to play important roles in cancer development and cell differentiation. Based on these results, the reprogrammed cancer cells can serve as the ideal model system to study the molecular mechanisms of tumorigenesis and the properties of cancer stem cells to establish critical approaches for cancer and regenerative medicine.

Conclusion

Here we have reviewed the tumorigenicity risks associated with iPSCs. Recently, genetic alterations, including copy-number variations and protein-coding point mutations,

were observed during the reprogramming process by using high-resolution genetic approaches [95,96]. Point mutations were enriched in cancer-related genes [95]. These studies strongly suggest iPSCs have a high tumorigenicity potential. Thus, specifically, to achieve the therapeutic application of cancer cells via the reprogramming method, transfection of tumor suppressor genes, such as *p16^{INK4a}/RB*, *p21^{CIP1}*, *p14^{ARF}* and *p53*, combined with pluripotent factors, such as OCT4 or SOX2, might be preferable compared with viral transduction of potent oncogenes. Importantly, reprogramming and senescence are related processes, as shown by studies demonstrating that the reprogramming of cells is more challenging in cells that are closer to the onset of senescence [69]. The expression of reprogramming factors triggers RIS by activating several tumor-suppressive mechanisms. In addition, gene expression profiling studies have revealed that signature genes that are activated during reprogramming are common to these antiproliferative responses [69]. The small number of reports on the reprogramming of human primary cancer cells limits our ability to decipher the biological or technical barriers that prevent the reprogramming of cancer cells. However, we emphasize that human pluripotent stem cells should be checked to eliminate the possibility of any mutations in tumor suppressor genes, as they may lead to tumorigenesis after transfer to patients.

Abbreviations

ESC: embryonic stem cell; full-iPSC: fully committed induced pluripotent stem cell; iPSC: induced pluripotent stem cell; mTOR: mammalian target of rapamycin; pre-iPSC: pre-induced pluripotent stem cell; RIS: reprogramming-induced senescence; ROS: reactive oxygen species.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

Y-CL and C-SL contributed to study conception, manuscript writing and data analysis. YM, KH and YN critically revised the paper. Y-CL, KKY and SS

contributed to study conception, data analysis, and manuscript writing and critically revised the paper. All authors read and approved the final manuscript.

Acknowledgments

The authors thank Drs DC Wu, M Noguchi, K Kato, H Miyoshi and K Nagata for cells, reagents, and valuable suggestions. We also thank Ms SW Wang and CC Ku for support in accomplishing the experiments. This work was partially supported by grants from the National Science Council (NSC-100-2320-B-037-020, NSC-102-2320-B-037-047-My3, and NSC-102-2314-B-037-004-My2), the National Health Research Institutes (NHRI-Ex102-10109BI, NHRI-102A1-PDCO-03010201), the Department of Education (KMU-EM-93-3), and the Kaohsiung Medical University (KMUER-006), Taiwan.

Author details

¹School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, 100 Shin-Chuan 1st Road, Kaohsiung 807, Taiwan. ²Cancer Center, Kaohsiung Medical University Hospital, 100, Tzyou 1st Road, Kaohsiung 807, Taiwan. ³College of Engineering, Nihon University, Koriyama, Fukushima 963-8642, Japan. ⁴Department of Zootechnical Science, Tokyo University of Agriculture, Atsugi, Kanagawa 243-0034, Japan. ⁵Cell Engineering Division, RIKEN BioResource Center, Tsukuba, Ibaraki 305-0074, Japan. ⁶Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, 100 Shin-Chuan 1st Road, Kaohsiung 807, Taiwan. ⁷Department of Biological Science, National Sun Yat-sen University, 70 Lien-hai Road, Kaohsiung 804, Taiwan. ⁸Saito Laboratory of Cell Technology, Yaita, Tochigi 329-1571, Japan. ⁹School of Science and Engineering, Teikyo University, Utsunomiya, Tochigi 320-8551, Japan.

Published: 28 Apr 2014

References

- Evans MJ, Kaufman MH: Establishment in culture of pluripotential cells from mouse embryos. *Nature* 1981, **292**:154–156.
- Wilmot I, Schnieke AE, McWhir J, Kind AJ, Campbell KH: Viable offspring derived from fetal and adult mammalian cells. *Nature* 1997, **385**:810–813.
- Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 2006, **126**:663–676.
- Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA: Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. *Nat Biotechnol* 2008, **26**:795–797.
- Ichida JK, Blanchard J, Lam K, Son EY, Chung JE, Egli D, Loh KM, Carter AC, Di Giorgio FP, Koszka K, Huangfu D, Akutsu H, Liu DR, Rubin LL, Eggan K: A small-molecule inhibitor of TGF-beta signaling replaces Sox2 in reprogramming by inducing Nanog. *Cell Stem Cell* 2009, **5**:491–503.
- Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T, Hao E, Hayek A, Deng H, Ding S: Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. *Cell Stem Cell* 2009, **4**:16–19.
- Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, Guenther MG, Kumar RM, Murray HL, Jenner RG, Gifford DK, Melton DA, Jaenisch R, Young RA: Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell* 2005, **122**:947–956.
- Hochedlinger K, Yamada Y, Beard C, Jaenisch R: Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. *Cell* 2005, **121**:465–477.
- Loh YH, Wu Q, Chew JL, Vega VB, Zhang W, Chen X, Bourque G, George J, Leong B, Liu J, Wong KY, Sung KW, Lee CW, Zhao XD, Chiu KP, Lipovich L, Kuznetsov VA, Robson P, Stanton LW, Wei CL, Ruan Y, Lim B, Ng HH: The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. *Nat Genet* 2006, **38**:431–440.
- van den Berg DL, Snoek T, Mullin NP, Yates A, Bezstarosti K, Demmers J, Chambers I, Poot RA: An Oct4-centered protein interaction network in embryonic stem cells. *Cell Stem Cell* 2010, **6**:369–381.
- Ye S, Li P, Tong C, Ying QL: Embryonic stem cell self-renewal pathways converge on the transcription factor Tfcp2l1. *EMBO J* 2013, **32**:2548–2560.
- Martello G, Bertone P, Smith A: Identification of the missing pluripotency mediator downstream of leukaemia inhibitory factor. *EMBO J* 2013, **32**:2561–2574.
- Kielman MF, Rindapaa M, Gaspar C, van Poppel N, Breukel C, van Leeuwen S, Taketo MM, Roberts S, Smits R, Fodde R: Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling. *Nat Genet* 2002, **32**:594–605.
- Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH: Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. *Nat Med* 2004, **10**:55–63.
- Ogawa K, Nishinakamura R, Iwamatsu Y, Shimamoto D, Niwa H: Synergistic action of Wnt and LIF in maintaining pluripotency of mouse ES cells. *Biochem Biophys Res Commun* 2006, **343**:159–166.
- Takao Y, Yokota T, Koide H: Beta-catenin up-regulates Nanog expression through interaction with Oct-3/4 in embryonic stem cells. *Biochem Biophys Res Commun* 2007, **353**:699–705.
- Marson A, Foreman R, Chevalier B, Bilodeau S, Kahn M, Young RA, Jaenisch R: Wnt signaling promotes reprogramming of somatic cells to pluripotency. *Cell Stem Cell* 2008, **3**:132–135.
- Otero JJ, Fu W, Kan L, Cuadra AE, Kessler JA: Beta-catenin signaling is required for neural differentiation of embryonic stem cells. *Development* 2004, **131**:3545–3557.
- Lindsley RC, Gill JG, Kyba M, Murphy TL, Murphy KM: Canonical Wnt signaling is required for development of embryonic stem cell-derived mesoderm. *Development* 2006, **133**:3787–3796.
- Abu-Remaileh M, Gerson A, Farago M, Nathan G, Alkalay I, Zins Rousso S, Gur M, Fainsod A, Bergman Y: Oct-3/4 regulates stem cell identity and cell fate decisions by modulating Wnt/beta-catenin signalling. *EMBO J* 2010, **29**:3236–3248.
- Wang J, Xie LY, Allan S, Beach D, Hannon GJ: Myc activates telomerase. *Genes Dev* 1998, **12**:1769–1774.
- Clark AT: The stem cell identity of testicular cancer. *Stem Cell Rev* 2007, **3**:49–59.
- Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, Sun L, Yang X, Wang Y, Zhang Y, Shang Y: The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. *J Biol Chem* 2008, **283**:17969–17978.
- Krizhanovsky V, Lowe SW: Stem cells: the promises and perils of p53. *Nature* 2009, **460**:1085–1086.
- Scaffidi P, Misteli T: In vitro generation of human cells with cancer stem cell properties. *Nat Cell Biol* 2011, **13**:1051–1061.
- Spike BT, Wahl GM: p53, stem cells, and reprogramming: tumor suppression beyond guarding the genome. *Genes Cancer* 2011, **2**:404–419.
- Kinzler KW, Vogelstein B: Cancer-susceptibility genes. Gatekeepers and caretakers. *Nature* 1997, **386**:761–763.
- He S, Nakada D, Morrison SJ: Mechanisms of stem cell self-renewal. *Annu Rev Cell Dev Biol* 2009, **25**:377–406.
- Krishnamurthy J, Ramsey MR, Ligon KL, Torrice C, Koh A, Bonner-Weir S, Sharpless NE: p16INK4a induces an age-dependent decline in islet regenerative potential. *Nature* 2006, **443**:453–457.
- Janzen V, Forkert R, Fleming HE, Saito Y, Waring MT, Dombkowski DM, Cheng T, DePinho RA, Sharpless NE, Scadden DT: Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. *Nature* 2006, **443**:421–426.
- Molofsky AV, Pardoll R, Iwashita T, Park IK, Clarke MF, Morrison SJ: Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. *Nature* 2003, **425**:962–967.
- Lee JY, Nakada D, Yilmaz OH, Tothova Z, Joseph NM, Lim MS, Gilliland DG, Morrison SJ: mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion. *Cell Stem Cell* 2010, **7**:593–605.
- Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranion N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, Park SH, Thompson T, Karsenty G, Bradley A, Donehower LA: p53 mutant mice that display early ageing-associated phenotypes. *Nature* 2002, **415**:45–53.
- Dumble M, Moore L, Chambers SM, Geiger H, Van Zant G, Goodell MA, Donehower LA: The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. *Blood* 2007, **109**:1736–1742.
- Gannon HS, Donehower LA, Lyle S, Jones SN: Mdm2-p53 signaling regulates epidermal stem cell senescence and premature aging phenotypes in mouse skin. *Dev Biol* 2011, **353**:1–9.
- van Heemst D, Mooijaart SP, Beekman M, Schreuder J, de Craen AJ, Brandt BW, Slagboom PE, Westendorp RG, Long Life study group: Variation in the human TP53 gene affects old age survival and cancer mortality. *Exp Gerontol* 2005, **40**:11–15.

37. Schoppy DW, Ruzankina Y, Brown EJ: **Removing all obstacles: a critical role for p53 in promoting tissue renewal.** *Cell Cycle* 2010, **9**:1313–1319.
38. Ruzankina Y, Pinzon-Guzman C, Asare A, Ong T, Pontano L, Cotsarelis G, Zediak VP, Velez M, Bhandoola A, Brown EJ: **Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss.** *Cell Stem Cell* 2007, **1**:113–126.
39. Begus-Nahrmann Y, Lechel A, Obenauf AC, Nalapareddy K, Peit E, Hoffmann E, Schlaudraff F, Liss B, Schirmacher P, Kestler H, Danenberg E, Barker N, Clevers H, Speicher MR, Rudolph KL: **p53 deletion impairs clearance of chromosomal-instable stem cells in aging telomere-dysfunctional mice.** *Nat Genet* 2009, **41**:1138–1143.
40. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, DePinho RA: **p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.** *Nature* 2008, **455**:1129–1133.
41. Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI, Martins CP: **Selective activation of p53-mediated tumour suppression in high-grade tumours.** *Nature* 2010, **468**:567–571.
42. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, Jacks T: **Stage-specific sensitivity to p53 restoration during lung cancer progression.** *Nature* 2010, **468**:572–575.
43. Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K: **Immortalization eliminates a roadblock during cellular reprogramming into iPS cells.** *Nature* 2009, **460**:1145–1148.
44. Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O, Molchadsky A, Goldfinger N, Brenner O, Rotter V: **Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.** *J Exp Med* 2010, **207**:2127–2140.
45. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Izpisua Belmonte JC: **Linking the p53 tumour suppressor pathway to somatic cell reprogramming.** *Nature* 2009, **460**:1140–1144.
46. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S: **Suppression of induced pluripotent stem cell generation by the p53-p21 pathway.** *Nature* 2009, **460**:1132–1135.
47. Marion RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA: **A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity.** *Nature* 2009, **460**:1149–1153.
48. Wallace DC: **A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine.** *Annu Rev Genet* 2005, **39**:359–407.
49. Plath K, Lowry WE: **Progress in understanding reprogramming to the induced pluripotent state.** *Nat Rev Genet* 2011, **12**:253–265.
50. Zhou H, Ding S: **Evolution of induced pluripotent stem cell technology.** *Curr Opin Hematol* 2010, **17**:276–280.
51. Ding L, Zhao X, Huang Y, Du Q, Dong F, Zhang H, Song X, Zhang W, Tong D: **Regulation of ROS in transmissible gastroenteritis virus-activated apoptotic signaling.** *Biochem Biophys Res Commun* 2013, **442**:33–37.
52. Ono C, Ninomiya A, Yamamoto S, Abe T, Wen X, Fukuhara T, Sasai M, Yamamoto M, Saitoh T, Satoh T, Kawai T, Ishii KJ, Akira S, Okamoto T, Matsuura Y: **Innate immune response induced by baculovirus attenuates transgene expression in mammalian cells.** *J Virol* 2014, **88**:2157–2167.
53. Li H, Collado M, Villasante A, Strati K, Ortega S, Canamero M, Blasco MA, Serrano M: **The Ink4/Arf locus is a barrier for iPS cell reprogramming.** *Nature* 2009, **460**:1136–1139.
54. Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S: **Hypoxia enhances the generation of induced pluripotent stem cells.** *Cell Stem Cell* 2009, **5**:237–241.
55. Mah N, Wang Y, Liao MC, Prigione A, Jozefczuk J, Lichtner B, Wolfrum K, Haltmeier M, Flottmann M, Schaefer M, Hahn A, Mrowka R, Klipp E, Andrade-Navarro MA, Adjaye J: **Molecular insights into reprogramming-initiation events mediated by the OSKM gene regulatory network.** *PLoS One* 2011, **6**:e24351.
56. Esteban MA, Wang T, Qin B, Yang J, Qin D, Cai J, Li W, Weng Z, Chen J, Ni S, Chen K, Li Y, Liu X, Xu J, Zhang S, Li F, He W, Labuda K, Song Y, Peterbauer A, Wolbank S, Redl H, Zhong M, Cai D, Zeng L, Pei D: **Vitamin C enhances the generation of mouse and human induced pluripotent stem cells.** *Cell Stem Cell* 2010, **6**:71–79.
57. Wang T, Chen K, Zeng X, Yang J, Wu Y, Shi X, Qin B, Zeng L, Esteban MA, Pan G, Pei D: **The histone demethylases Jhdml1a/1b enhance somatic cell reprogramming in a vitamin-C-dependent manner.** *Cell Stem Cell* 2011, **9**:575–587.
58. Chen T, Shen L, Yu J, Wan H, Guo A, Chen J, Long Y, Zhao J, Pei G: **Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells.** *Aging cell* 2011, **10**:908–911.
59. Menendez JA, Vellon L, Oliveras-Ferreras C, Cufi S, Vazquez-Martin A: **mTOR-regulated senescence and autophagy during reprogramming of somatic cells to pluripotency: a roadmap from energy metabolism to stem cell renewal and aging.** *Cell Cycle* 2011, **10**:3658–3677.
60. Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I, Pinho S, Silva JC, Azuara V, Walsh M, Vallier L, Gil J: **Senescence impairs successful reprogramming to pluripotent stem cells.** *Genes Dev* 2009, **23**:2134–2139.
61. Collado M, Blasco MA, Serrano M: **Cellular senescence in cancer and aging.** *Cell* 2007, **130**:223–233.
62. Pereira CF, Terranova R, Ryan NK, Santos J, Morris KJ, Cui W, Merckenschlager M, Fisher AG: **Heterokaryon-based reprogramming of human B lymphocytes for pluripotency requires Oct4 but not Sox2.** *PLoS Genet* 2008, **4**:e1000170.
63. Mikkelsen TS, Hanna J, Zhang X, Ku M, Wernig M, Schorderet P, Bernstein BE, Jaenisch R, Lander ES, Meissner A: **Dissecting direct reprogramming through integrative genomic analysis.** *Nature* 2008, **454**:49–55.
64. Sridharan R, Tchieu J, Mason MJ, Yachechko R, Kuoy E, Horvath S, Zhou Q, Plath K: **Role of the murine reprogramming factors in the induction of pluripotency.** *Cell* 2009, **136**:364–377.
65. Molchadsky A, Rivlin N, Brosh R, Rotter V, Sarig R: **p53 is balancing development, differentiation and de-differentiation to assure cancer prevention.** *Carcinogenesis* 2010, **31**:1501–1508.
66. Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, Smith A: **Promotion of reprogramming to ground state pluripotency by signal inhibition.** *PLoS Biol* 2008, **6**:e253.
67. Yamanaka S: **Strategies and new developments in the generation of patient-specific pluripotent stem cells.** *Cell Stem Cell* 2007, **1**:39–49.
68. Zhao Y, Yin X, Qin H, Zhu F, Liu H, Yang W, Zhang Q, Xiang C, Hou P, Song Z, Liu Y, Yong J, Zhang P, Cai J, Liu M, Li H, Li Y, Qu X, Cui K, Zhang W, Xiang T, Wu Y, Zhao Y, Liu C, Yu C, Yuan K, Lou J, Ding M, Deng H: **Two supporting factors greatly improve the efficiency of human iPS cell generation.** *Cell Stem Cell* 2008, **3**:475–479.
69. Banito A, Gil J: **Induced pluripotent stem cells and senescence: learning the biology to improve the technology.** *EMBO Rep* 2010, **11**:353–359.
70. Lane DP: **Cancer. p53, guardian of the genome.** *Nature* 1992, **358**:15–16.
71. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, Xu Y: **p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression.** *Nat Cell Biol* 2005, **7**:165–171.
72. Pierce GB, Speers WC: **Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation.** *Cancer Res* 1988, **48**:1996–2004.
73. Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW: **p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.** *Genes Dev* 2010, **24**:1389–1402.
74. Pelengaris S, Khan M, Evan G: **c-MYC: more than just a matter of life and death.** *Nat Rev Cancer* 2002, **2**:764–776.
75. Chen J, Liu H, Liu J, Qi J, Wei B, Yang J, Liang H, Chen Y, Chen J, Wu Y, Guo L, Zhu J, Zhao X, Peng T, Zhang Y, Chen S, Li X, Li D, Wang T, Pei D: **H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs.** *Nat Genet* 2013, **45**:34–42.
76. Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creighton MP, van Oudenaarden A, Jaenisch R: **Direct cell reprogramming is a stochastic process amenable to acceleration.** *Nature* 2009, **462**:595–601.
77. Blum B, Benvenisty N: **The tumorigenicity of diploid and aneuploid human pluripotent stem cells.** *Cell Cycle* 2009, **8**:3822–3830.
78. Draper JS, Moore HD, Ruban LN, Gokhale PJ, Andrews PW: **Culture and characterization of human embryonic stem cells.** *Stem Cells Dev* 2004, **13**:325–336.
79. Imreh MP, Gertow K, Cedervall J, Unger C, Holmberg K, Szoke K, Csoregh L, Fried G, Dilber S, Blennow E, Ahrlund-Richter L: **In vitro culture conditions favoring selection of chromosomal abnormalities in human ES cells.** *J Cell Biochem* 2006, **99**:508–516.

80. Baker DE, Harrison NJ, Maltby E, Smith K, Moore HD, Shaw PJ, Heath PR, Holden H, Andrews PW: **Adaptation to culture of human embryonic stem cells and oncogenesis in vivo.** *Nat Biotechnol* 2007, **25**:207–215.
81. Mayshar Y, Ben-David U, Lavon N, Biancotti JC, Yakir B, Clark AT, Plath K, Lowry WE, Benvenisty N: **Identification and classification of chromosomal aberrations in human induced pluripotent stem cells.** *Cell Stem Cell* 2010, **7**:521–531.
82. Saito S, Lin YC, Murayama Y, Hashimoto K, Yokoyama KK: **Human amnion-derived cells as a reliable source of stem cells.** *Curr Mol Med* 2012, **12**:1340–1349.
83. Ben-David U, Benvenisty N: **The tumorigenicity of human embryonic and induced pluripotent stem cells.** *Nat Rev Cancer* 2011, **11**:268–277.
84. Miki T, Mitamura K, Ross MA, Stolz DB, Strom SC: **Identification of stem cell marker-positive cells by immunofluorescence in term human amnion.** *J Reprod Immunol* 2007, **75**:91–96.
85. De Coppi P, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, Perin L, Mostoslavsky G, Serre AC, Snyder EY, Yoo JJ, Furth ME, Soker S, Atala A: **Isolation of amniotic stem cell lines with potential for therapy.** *Nat Biotechnol* 2007, **25**:100–106.
86. Walther G, Gekas J, Bertrand OF: **Amniotic stem cells for cellular cardiomyoplasty: promises and premises.** *Catheter Cardiovasc Interv* 2009, **73**:917–924.
87. Diaz-Prado S, Muinos-Lopez E, Hermida-Gomez T, Cicione C, Rendal-Vazquez ME, Fuentes-Boquete I, de Toro FJ, Blanco FJ: **Human amniotic membrane as an alternative source of stem cells for regenerative medicine.** *Differentiation* 2011, **81**:162–171.
88. Wolfrum K, Wang Y, Prigione A, Sperling K, Lehrach H, Adjaye J: **The LARGE principle of cellular reprogramming: lost, acquired and retained gene expression in foreskin and amniotic fluid-derived human iPSC cells.** *PLoS One* 2010, **5**:e13703.
89. Ma T, Xie M, Laurent T, Ding S: **Progress in the reprogramming of somatic cells.** *Circ Res* 2013, **112**:562–574.
90. Brons IG, Smithers LE, Trotter MW, Rugg-Gunn P, Sun B, de Sousa Lopes SM C, Howlett SK, Clarkson A, Ahrlund-Richter L, Pedersen RA, Vallier L: **Derivation of pluripotent epiblast stem cells from mammalian embryos.** *Nature* 2007, **448**:191–195.
91. Kim JB, Sebastiano V, Wu G, Arauzo-Bravo MJ, Sasse P, Gentile L, Ko K, Ruau D, Ehrich M, van den Boom D, Meyer J, Hubner K, Bernemann C, Ortmeier C, Zenke M, Fleischmann BK, Zaehres H, Scholer HR: **Oct4-induced pluripotency in adult neural stem cells.** *Cell* 2009, **136**:411–419.
92. Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, Nagano H, Sekimoto M, Doki Y, Mori M: **Defined factors induce reprogramming of gastrointestinal cancer cells.** *Proc Natl Acad Sci U S A* 2010, **107**:40–45.
93. Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu DT, Chen DT, Ying SY: **Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state.** *RNA* 2008, **14**:2115–2124.
94. Liang G, Zhang Y: **Embryonic stem cell and induced pluripotent stem cell: an epigenetic perspective.** *Cell Res* 2013, **23**:49–69.
95. Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, Canto I, Giorgetti A, Israel MA, Kiskinis E, Lee JH, Loh YH, Manos PD, Montserrat N, Panopoulos AD, Ruiz S, Wilbert ML, Yu J, Kirkness EF, Izpisua Belmonte JC, Rossi DJ, Thomson JA, Eggan K, Daley GQ, Goldstein LS, Zhang K: **Somatic coding mutations in human induced pluripotent stem cells.** *Nature* 2011, **471**:63–67.
96. Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Narva E, Ng S, Sourour M, Hamalainen R, Olsson C, Lundin K, Mikkola M, Trokovic R, Peitz M, Brustle O, Bazett-Jones DP, Alitalo K, Lahesmaa R, Nagy A, Otonkoski T: **Copy number variation and selection during reprogramming to pluripotency.** *Nature* 2011, **471**:58–62.

10.1186/scrt447

Cite this article as: Lin et al.: Role of tumor suppressor genes in the cancer-associated reprogramming of human induced pluripotent stem cells. *Stem Cell Research & Therapy* 2014, 5:58